Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasms 1

Interventions

Cyclophosphamide 548pembrolizumab 382Radiotherapy 363Bevacizumab 359Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × gadobutrol × Clear all
NCT00375830 2023-12-12

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Stanford University

Phase 2 Completed
114 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT03404648 2021-02-08

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

Mayo Clinic

Phase 3 Completed
19 enrolled 5 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡